顧みられない熱帯病(NTD)治療の世界市場予測・分析:種類別・地域別

◆英語タイトル:Neglected Tropical Disease Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR31423
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年6月19日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、米州、アジア太平洋、EMEA(ヨーロッパ・中東・アフリカ)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、顧みられない熱帯病(NTD)治療の世界市場について調べ、顧みられない熱帯病(NTD)治療の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、顧みられない熱帯病(NTD)治療の市場規模をセグメンテーション別(種類別(駆虫薬、抗菌薬、抗ウイルス薬))と地域別(グローバル、米州、アジア太平洋、EMEA(ヨーロッパ・中東・アフリカ))に分けて算出しました。
・サマリー
・レポートの範囲
・顧みられない熱帯病(NTD)治療の市場状況
・顧みられない熱帯病(NTD)治療の市場規模
・顧みられない熱帯病(NTD)治療の市場予測
・顧みられない熱帯病(NTD)治療の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(駆虫薬、抗菌薬、抗ウイルス薬)
・顧みられない熱帯病(NTD)治療の顧客状況
・主要地域別市場規模:グローバル、米州、アジア太平洋、EMEA(ヨーロッパ・中東・アフリカ)
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Neglected Tropical Disease Treatment Market: About this market

Neglected tropical diseases are caused by pathogens such as parasites, bacteria, and virus. Technavio’s neglected tropical disease treatment market considers the treatment of neglected tropical diseases using antiparasitic drugs, antibacterial drugs, and antiviral drugs. Our analysis also considers growth opportunities in Asia, North America, and ROW. In 2018, the antiparasitic drugs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing prevalence of parasite-infected diseases will play a significant role in the antiparasitic drugs segment to maintain its market position. Also, our global neglected tropical disease treatment market report looks at factors such as initiatives to increase awareness and access to medicines for neglected tropical diseases, high morbidity rates, and increased funding in R&D. However, challenges associated with diagnosing neglected tropical diseases, challenges associated with drug discovery for neglected tropical diseases, and the increase in drug resistance may hamper the growth of the neglected tropical disease treatment industry over the forecast period.

Global Neglected Tropical Disease Treatment Market: Overview

Initiatives to increase awareness and access to medicines for neglected tropical diseases

The growing prevalence of neglected tropical diseases in tropical and subtropical countries has led many organizations across the world to increase awareness and to ensure easy availability of drugs for the treatment of such diseases. For instance, the Global Buruli Ulcer initiative by the World Health Organization (WHO) is aimed at improving awareness about Buruli ulcer disease. Several other organizations across the world are taking initiatives to improve the access of medicines, vaccines, and diagnostics for the treatment of neglected tropical diseases in low and middle-income countries. These developments are expected to drive the growth of the global neglected tropical disease treatment market size at a CAGR of almost 5% during the forecast period.

Development and approval of therapeutics for neglected tropical diseases

The high incidence of neglected tropical diseases such as dengue, lymphatic filariasis, trachoma, and leishmaniasis have encouraged researchers to focus on developing therapeutics for such diseases. For instance, researchers at the University Hospitals Cleveland Medical Center have developed a drug to treat patients with lymphatic filariasis. The drug is currently in Phase II of clinical trials. Many such advancements in drug development will aid in the treatment of many neglected tropical diseases and also fuel the market’s growth.

For the detailed list of factors that will drive the global neglected tropical disease market size during the forecast period 2019-2023, click here

Competitive Landscape

With the presence of a few players, the global neglected tropical disease treatment market is fairly concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading drug manufacturers, that include Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, and Pfizer Inc.

Also, the neglected tropical disease treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Antiparasitic drugs – Market size and forecast 2018-2023

Antibacterial drugs – Market size and forecast 2018-2023

Antiviral drugs – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

ROW – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

North America – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Market trends

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bayer AG

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Novartis AG

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global infectious disease treatment market

Exhibit 02: Segments of global infectious disease treatment market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Diseases caused by organisms

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Type – Market share 2018-2023 (%)

Exhibit 19: Comparison by type

Exhibit 20: Antiparasitic drugs – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Antiparasitic drugs – Year-over-year growth 2019-2023 (%)

Exhibit 22: Antibacterial drugs – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Antibacterial drugs – Year-over-year growth 2019-2023 (%)

Exhibit 24: Antiviral drugs – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Antiviral drugs – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by type

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 32: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 34: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: North America – Year-over-year growth 2019-2023 (%)

Exhibit 36: Key leading countries

Exhibit 37: Market opportunity

Exhibit 38: Impact of drivers and challenges

Exhibit 39: Vendor landscape

Exhibit 40: Landscape disruption

Exhibit 41: Vendors covered

Exhibit 42: Vendor classification

Exhibit 43: Market positioning of vendors

Exhibit 44: Bayer AG – Vendor overview

Exhibit 45: Bayer AG – Business segments

Exhibit 46: Bayer AG – Organizational developments

Exhibit 47: Bayer AG – Geographic focus

Exhibit 48: Bayer AG – Segment focus

Exhibit 49: Bayer AG – Key offerings

Exhibit 50: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 51: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 52: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 53: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 54: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 55: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 56: GlaxoSmithKline Plc – Vendor overview

Exhibit 57: GlaxoSmithKline Plc – Business segments

Exhibit 58: GlaxoSmithKline Plc – Organizational developments

Exhibit 59: GlaxoSmithKline Plc – Geographic focus

Exhibit 60: GlaxoSmithKline Plc – Segment focus

Exhibit 61: GlaxoSmithKline Plc – Key offerings

Exhibit 62: Novartis AG – Vendor overview

Exhibit 63: Novartis AG – Business segments

Exhibit 64: Novartis AG – Organizational developments

Exhibit 65: Novartis AG – Geographic focus

Exhibit 66: Novartis AG – Segment focus

Exhibit 67: Novartis AG – Key offerings

Exhibit 68: Pfizer Inc. – Vendor overview

Exhibit 69: Pfizer Inc. – Business segments

Exhibit 70: Pfizer Inc. – Organizational developments

Exhibit 71: Pfizer Inc. – Geographic focus

Exhibit 72: Pfizer Inc. – Segment focus

Exhibit 73: Pfizer Inc. – Key offerings

Exhibit 74: Validation techniques employed for market sizing

Exhibit 75: Definition of market positioning of vendors



【掲載企業】

Bayer AG、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline Plc、Novartis AG、Pfizer Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[顧みられない熱帯病(NTD)治療の世界市場予測・分析:種類別・地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆